

6 November 2024

Company Announcements Australian Securities Exchange 20 Bridge Street SYDNEY NSW 2000

CORRECTION TO APPENDIX 3Y

Attached is a corrected Appendix 3Y for Dr Katharine Giles.

On 22 February 2024, the AKMC Superannuation Fund A/C associated with Dr Giles acquired 250 shares in Sonic Healthcare Limited ("Sonic"; ASX:SHL; ADR:SKHHY) through an on-market purchase.

As Dr Giles has a deemed notifiable interest in the shares acquired by AKMC Superannuation Fund A/C, an Appendix 3Y should have been lodged for Dr Giles at the time to indicate the relevant change of director's interest, but was not lodged due to an oversight in the Director notifying Sonic of the trade.

As the information was not included in the last Appendix 3Y lodged for Dr Giles on 27 May 2024, the attached Appendix 3Y is lodged to correct that disclosure.

Sonic is aware of its listing rule obligations in relation to these disclosures and specifically listing rules 3.19A and 3.19B.

Sonic has informed all Directors of the disclosure requirements set out in the listing rules 3.19A and 3.19B and s205G(1) of the Corporations Act 2001, and has documented the need to notify the company of trading in letters of appointment of Directors and in the company's Securities Trading Policy. Directors are reminded of these requirements from time to time, generally including when seeking approval to enter into a trade in the company's shares.

Sonic considers that it currently has appropriate arrangements in place to ensure timely notifications going forward for all Directors' interests including ongoing compliance with listing rule 3.19B.

This announcement has been authorised by Sonic's Company Secretary, whose contact details for further information are as follows:

Paul Alexander

Company Secretary Sonic Healthcare

Telephone: +61 2 9855 5404

Email: paul.alexander@sonichealthcare.com.au

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	SONIC HEALTHCARE LIMITED
ABN	24 004 196 909

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	KATHARINE GILES
Date of last notice	27 MAY 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect	
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Fully paid ordinary shares in Sonic Healthcare Limited held via AKMC Superannuation Fund A/C	
Date of change	22 February 2024	
No. of securities held prior to change	2,500 fully paid ordinary shares in Sonic Healthcare Limited	
Class	Fully paid ordinary shares in Sonic Healthcare Limited	
Number acquired	250 fully paid ordinary shares in Sonic Healthcare Limited	
Number disposed	Nil	
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$28.89 per share	
No. of securities held after change	2,750 fully paid ordinary shares in Sonic Healthcare Limited	

⁺ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

On-market purchase

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder	
(if issued securities)	
(ii issued securities)	
Date of change	
zato er emange	
No. and class of securities to which	
interest related prior to change	
Note: Details are only required for a contract in	
relation to which the interest has changed	
Interest acquired	
into oct doquirod	
Interest disposed	
•	
Value/Consideration	
Note: If consideration is non-cash, provide details	
and an estimated valuation	
Interest often showns	
Interest after change	

Part 3 – *Closed period

Were the interests in the securities or contracts detailed above traded during a *closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

Appendix 3Y Page 2 01/01/2011

⁺ See chapter 19 for defined terms.